{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:36:25Z","timestamp":1793568985809,"version":"4.5.0"},"reference-count":53,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Atypical Chronic Myeloid Leukemia, BCR-ABL1 negative (aCML) is a rare hematological entity, included in the group of myelodysplastic (MDS)\/myeloproliferative (MPN) overlap syndromes. It is characterized by an aggressive course, a high rate of acute myeloid leukemia (AML) transformation, and a dismal outcome. The clinical presentation includes splenomegaly and leukocytosis with neutrophilia and left-shifted granulocytosis accompanied by granulocytic dysplasia and sometimes multilineage dysplasia. In past years, the disease incidence was likely underestimated, as diagnosis was only based on morphological features. Recently, the improving knowledge in the molecular biology of MDS\/MPN neoplasms has made it possible to distinguish aCML from other overlapping syndromes, basing on next generation sequencing. Among the most commonly mutated genes, several involve the Jak-STAT, MAPK, and ROCK signaling pathways, which could be actionable with targeted therapies that are already used in clinical practice, opening the way to tailored treatment in aCML. However, currently, there are few data available for small samples, and allogeneic transplant remains the only curative option for eligible patients.<\/jats:p>","DOI":"10.3390\/medicina57101104","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T22:42:18Z","timestamp":1634251338000},"page":"1104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-9054","authenticated-orcid":false,"given":"Alessia","family":"Castellino","sequence":"first","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, Via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Santambrogio","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, Via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rapezzi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, Via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, Via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H.C.E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, World Health Organization. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cris\u00e0, E., Nicolosi, M., Ferri, V., Favini, C., Gaidano, G., and Patriarca, A. (2020). Atypical Chronic Myeloid Leukemia: Where Are We Now?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186862"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_6","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/2040620715607416","article-title":"Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: A retrospective analysis of the Surveillance, Epidemiology and End Results database","volume":"6","author":"Giri","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/fon-2017-0334","article-title":"Atypical chronic myeloid leukemia: A rare entity with management challenges","volume":"14","author":"Dhakal","year":"2018","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hon.2501","article-title":"Atypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group","volume":"36","author":"Biecek","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.leukres.2007.07.004","article-title":"Clinical and prognostic features of patients with myelodysplastic\/myeloproliferative syndrome categorized as unclassified (MDS\/MPD-U) by WHO classification","volume":"32","author":"Cannella","year":"2008","journal-title":"Leuk Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR Rearrangement\u2013Negative Chronic Myelogenous Leukemia Revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","article-title":"Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable","volume":"101","author":"Zoi","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Cuneo","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V78.1.205.205","article-title":"Philadelphianegative (Ph-) chronic myeloid leukemia (CML): Comparison with Ph1 CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique","volume":"78","author":"Martiat","year":"1991","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1046\/j.1432-1327.2001.02000.x","article-title":"Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET","volume":"268","author":"Minakuchi","year":"2001","journal-title":"Eur J Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.beha.2019.101133","article-title":"Atypical CML- the role of morphology and precision genomics","volume":"33","author":"Lasho","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-14-3100","article-title":"The colony-stimulating factor 3 receptor T640N mutation Is oncogenic, sensitive to JAK inhibition, and mimics T618I","volume":"22","author":"Maxson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00277-015-2366-3","article-title":"De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML","volume":"94","author":"Bartels","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Passerini","year":"2015","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/br.2013.48.3.178","article-title":"Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic\/myeloproliferative neoplasms","volume":"48","author":"Lim","year":"2013","journal-title":"Blood Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: A retrospective study from the chronic malignancies working party of the European Society for blood and marrow transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11899-016-0350-1","article-title":"An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS\/MPN-Unclassifiable, and MDS\/MPN-RS-T","volume":"11","author":"Talati","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.V75.2.445.445","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: A chronic myeloid leukemia with a distinct clinical course","volume":"75","author":"Kurzrock","year":"1990","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.1995.tb05157.x","article-title":"Philadelphia chromosome-negative chronic myeloid leukaemia: A report of 14 new cases","volume":"90","author":"Costello","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01715120","article-title":"Ph-negative and bcr-negative atypical chronic myelogenous leukemia: Biological features and clinical outcome","volume":"65","author":"Montefusco","year":"1992","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-\u03b1-2b therapy in BCR-ABL\u2013negative myeloproliferative disorders","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What\u2019s different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao","year":"2015","journal-title":"Hematology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-20deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","article-title":"Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia","volume":"56","author":"Tong","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3892\/ol.2015.3977","article-title":"Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases","volume":"11","author":"Jiang","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1078155215605662","article-title":"Activity of single-agent decitabine in atypical chronic myeloid leukemia","volume":"22","author":"Hausmann","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_39","first-page":"114","article-title":"The First Case of Decitabine Successfully in Treatment of Atypical Chronic Myeloid Leukemia with CEBPA Double Mutation","volume":"2","author":"Mao","year":"2013","journal-title":"Chemother. Open Access"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"key":"ref_44","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2015","journal-title":"Leuk. Res. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess","year":"2014","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"ref_51","first-page":"e414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cur\u0113us"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fonc.2015.00016","article-title":"Therapeutic re-activation of protein phosphatase 2A in acute myeloid leukemia","volume":"5","author":"Ramaswamy","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"51920","DOI":"10.18632\/oncotarget.17231","article-title":"SETBP1 dysregulation in congenital disorders and myeloid neoplasms","volume":"8","author":"Coccaro","year":"2017","journal-title":"Oncotarget"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:14:32Z","timestamp":1760166872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["medicina57101104"],"URL":"https:\/\/doi.org\/10.3390\/medicina57101104","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]}}}